--- title: "Could This New Drug Be The Safer Way To Fight Obesity?" description: "Skye Bioscience, Inc. announced positive Phase 1b study results for nimacimab, a drug targeting metabolic-associated steatotic liver disease (MASLD), at the EASD Annual Meeting. The study showed nimac" type: "news" locale: "en" url: "https://longbridge.com/en/news/258138612.md" published_at: "2025-09-19T18:19:20.000Z" --- # Could This New Drug Be The Safer Way To Fight Obesity? > Skye Bioscience, Inc. announced positive Phase 1b study results for nimacimab, a drug targeting metabolic-associated steatotic liver disease (MASLD), at the EASD Annual Meeting. The study showed nimacimab was safe and well-tolerated, with no serious adverse events. The company anticipates topline data from its Phase 2a obesity study by the end of the month, projecting 5%-8% weight loss. Analysts suggest nimacimab could be a promising alternative in the competitive obesity market, maintaining an Outperform rating on Skye shares, which rose 0.76% to $3.97. On Friday, **Skye Bioscience, Inc.** SKYE announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting. The study demonstrated that nimacimab was safe, well-tolerated, and exhibited predictable pharmacokinetics and low immunogenicity across multiple ascending dose cohorts. There were no serious adverse events, no discontinuations due to adverse events, and no evidence of neuropsychiatric safety signals. Gastrointestinal side effects were infrequent and mild, underscoring the potential differentiated tolerability profile of this peripheral CB1-inhibiting antibody. ***Also Read: Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data*** The Phase 1b study was previously conducted by **Bird Rock Bio, Inc.**, which Skye acquired in 2023. “These Phase 1b results provide an early glimpse of the benchmark safety and tolerability profile that we believe sets nimacimab apart within the broader anti-obesity medicine landscape,” said **Puneet Arora**, MD, MS, FACE, Chief Medical Officer of Skye Bioscience. “Obesity is a multi-factorial disease with overlapping pathways across key organs including the liver, adipose tissue, and muscle. While our immediate focus is on the upcoming topline readout from our CBeyond Phase 2a obesity study, these favorable findings in an obese, diabetic MASLD population help establish nimacimab’s potential role in the treatment of metabolic diseases.” Investment firm **William Blair** expects Phase 2a CBeyond 26-week topline data of nimacimab by the end of the month or early next quarter in obesity and overweight. Skye management has guided to placebo-adjusted weight loss expectations of 5%-8% for monotherapy and additive weight loss for the Wegovy combination, with no occurrences of neuropsychiatric events, forming the basis of the base case assumption. Analyst **Andy Hsieh** writes that cannabinoid receptor 1 (CB1R) inverse agonism/antagonism represents a promising modality that could serve as either an alternative or combination partner for GLP-1 receptor agonists, and first-generation CB1R antagonists and inverse agonists provide clinical validation for the approach. Specifically, negative modulation of CB1R appears to induce weight loss with a lower degree of adverse gastrointestinal events and muscle mass retention. While development of first-generation versions was halted due to psychiatric adverse events, the analyst writes that this headwind is mitigated by nimacimab's preferential targeting of peripherally located CB1 receptors through the use of an antibody, and initial Phase 1 data, along with recent preclinical experiments, support this hypothesis. William Blair recognizes that competition is fierce in the obesity space, owing in large part to the unprecedented success of GLP-1 receptor drugs, such as **Novo Nordisk's** NVO Ozempic and **Eli Lilly's** LLY Zepbound. However, given the sizable addressable market and the increasing focus on tolerability and maintaining patients on therapy, the analyst says that nimacimab's clinical success could translate into significant upside for investors. William Blair maintains the Outperform rating on Skye shares. **Price Action:** SKYE stock was trading higher by 0.76% to $3.97 at last check Friday. - ***Opendoor Army Dreams Of SuperBowl Ads While Stock Takes A Time-Out*** *Photo via Shutterstock* ### Related Stocks - [SKYE.US - Skye Bioscience](https://longbridge.com/en/quote/SKYE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Skye Bioscience 發佈了關於 Nimacimab 用於治療肥胖和代謝疾病的演示文稿 | Skye Bioscience Inc. 提供了關於 nimacimab 的詳細信息，這是一種針對 CB1 的抑制抗體，旨在治療肥胖和代謝疾病。報告顯示，nimacimab 與 GLP-1 療法結合使用時，在 26 周內實現了 13% 的體 | [Link](https://longbridge.com/en/news/272309211.md) | | Skye Bioscience 啓動 Nimacimab 用於肥胖治療的 2a 期臨牀試驗 | Skye Bioscience Inc. 已啓動 nimacimab 的 2a 期臨牀試驗，這是一種針對治療肥胖的 CB1 抑制劑抗體。該試驗還評估了 nimacimab 與 GLP-1R 激動劑 Wegovy® 的聯合使用。在 Keyst | [Link](https://longbridge.com/en/news/274145896.md) | | 日圓逢高必沽是基本策略｜周顯 | 周顯認為，日圓將繼續下跌，建議在高位時賣出。他提到英國和日本的歷史，指出兩國的衰落是不可避免的，尤其是日本在經歷過輝煌後，未來將面臨衰退。他對日本文化的熱愛與對未來的擔憂形成對比，認為未來十到二十年內，日本的精緻文化將逐漸消失，呼籲人們抓緊 | [Link](https://longbridge.com/en/news/275691465.md) | | Neumora Therapeutics 公佈了新的研發管線，專注於神經精神疾病和代謝疾病 | Neumora Therapeutics Inc. 宣佈了一條新的研發管線，專注於神經科學藥物開發，目標是神經精神疾病和代謝疾病。主要項目包括用於肥胖的 NMRA-215、用於阿爾茨海默病激動症的 NMRA-511、用於帕金森病的 NMRA | [Link](https://longbridge.com/en/news/275602847.md) | | Skye Bioscience 計劃在 2026 年第三季度啓動 Nimacimab 用於治療肥胖症的 2b 期臨牀試驗 | Skye Bioscience Inc. 已概述其 2026 年的企業展望，重點關注用於肥胖治療的 CB1 抑制抗體 nimacimab 的臨牀里程碑。主要目標包括在 2026 年第一季度提供第二階段 2a 試驗的中期數據更新，以及在 20 | [Link](https://longbridge.com/en/news/272265006.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.